Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Net Income towards Common Stockholders: 2012-2024

Historic Net Income towards Common Stockholders for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to -$64.0 million.

  • Theravance Biopharma's Net Income towards Common Stockholders rose 128.47% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 144.15%. This contributed to the annual value of -$64.0 million for FY2024, which is 15.94% down from last year.
  • According to the latest figures from FY2024, Theravance Biopharma's Net Income towards Common Stockholders is -$64.0 million, which was down 15.94% from -$55.2 million recorded in FY2023.
  • In the past 5 years, Theravance Biopharma's Net Income towards Common Stockholders registered a high of $1.1 billion during FY2022, and its lowest value of -$64.0 million during FY2024.
  • Its 3-year average for Net Income towards Common Stockholders is $341.6 million, with a median of -$55.2 million in 2023.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 1,642.60% in 2022, then plummeted by 104.82% in 2023.
  • Theravance Biopharma's Net Income towards Common Stockholders (Yearly) stood at $16.8 million in 2020, then soared by 290.60% to $65.6 million in 2021, then skyrocketed by 1,642.60% to $1.1 billion in 2022, then slumped by 104.82% to -$55.2 million in 2023, then decreased by 15.94% to -$64.0 million in 2024.